Displaying 1 - 7 of 7
| Active Ingredient | EFAVIRENZ |
| Therapeutic Class | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIB (NNRTI) |
| Indications |
In combination with other antiretrovirals for the treatment of HIV-1 infection. Efavirenz usually is used in HIV nonnucleoside reverse transcriptase inhibitor-based (NNRTI-based) regimens that includ More ... |
| Caution | Psychiatric disorders, rash, increases in liver enzymes. |
| Dose Range |
Adult: 600mg once daily on an empty stomach preferably at bedtime. Pediatric: 3 years and older and weighing between 10-40kg: 200mg-600mg once daily . |
| Drug Interactions | Efavirenz induces CYP3A and 2B6, and may alter plasma concentrations of drugs metabolized by these enzymes. |
| Pregnancy | Efavirenz may cause fetal harm if administered during the first trimester of pre More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | NEVIRAPINE |
| Therapeutic Class | NNRTI |
| Indications | For use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Nevirap ine reduces maternal to fetal HIV transmission. |
| Caution | Nevirapine is generally well-tolerated. The primary adverse effects are fever, nausea, and headache. However severe and life-threatening skin reactions, toxic epidermal necroly sis and Stevens-Johnson More ... |
| Dose Range | Adult: 200mg once daily for 14 day s, then increased to 200mg twice daily , in ombination with a nucleoside analogue antiretroviral agent. Pediatric: 2 months to 8 y ears: 4mg/kg/day for the first 14 day s followed by 7mg/kg twice daily . 8 y ea |
| Drug Interactions | |
| Pregnancy | The human pregnancy data for nevirapine suggest that the risk for embryo–fetal h More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR |
| Therapeutic Class | NRTI |
| Indications |
Indicated in combination with other anti-HIV medications for the treatment of HIV-1 for adults and children. |
| Caution | Nausea, vomiting, fatigue, headache, diarrhoea and loss of appetite. Fatal lactic acidosis and severe hep atomegaly with steatosis have been reported. Fatal hypersensitivity reactions include s More ... |
| Dose Range | Adult: Recommended dosing is 300mg orally twice daily with or without food. Pediatric: 3 months - 16 years of age is 8mg/kg orally twice daily (up to a maximum of 300mg twice daily ). Abacavir should be used in combination with other antiretrovirals. |
| Drug Interactions | Alcohol reduces the metabolism of abacavir. |
| Pregnancy | The animal data suggest moderate risk. Although the human pregnancy experience d More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DIDANOSINE |
| Therapeutic Class | NRTI |
| Indications | A first-line component of a combination antiretroviral therapy regimenfor HIV-1 infected p atients. |
| Caution | Diarrhoea, neuropathy , chills or fever, rash, abdominal pain,weakness, headache and nausea/vomiting. Serious toxicities have included pancreatitis and lactic acidosis (which may be fata More ... |
| Dose Range | Adult: weighing greater than 60kg, 200mg twice daily . Weighing less than or equal to 60kg, 125mg twice daily . Pediatric 8 months and older: 120mg/square meter twice daily . 2 weeks - 8 months: 100mg/square meter twice daily . Take on an empty stomach. |
| Drug Interactions | Coadministration of Didanosine and allopurinol is contraindicated because systemic exposures of Didanosine are increased, which may increase Didanosine-associated toxicity |
| Pregnancy | Reproduction studies have been performed in rats and rabbits at doses up to 12 a More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | LAMIVUDINE |
| Therapeutic Class | NRTI |
| Indications | A combination of oral lamivudine and oral zidovudine has p roduced significant and sustained increases in CD4+ counts and decreases in viral load in HIV-infected patients. Lamivudine is indicated for More ... |
| Caution | Diarrhoea, headache, fatigue, insomnia, arthralgias, myalgias, neuropathy, nasal signs and symptoms, elevated liver enzymes, skin rash, fever or chills, ear, nose and throat infections. Concurrent use More ... |
| Dose Range |
Adult: 150mg orally twice daily , or 300mg once daily . Pediatric 3 months - 16 years: 4mg/kg twice daily (up to a maximum dose of 150mg twice a day ). Chronic hep atitis B: 100mg orally daily for adults and 3mg/kg once daily (maximum daily dose = |
| Drug Interactions | |
| Pregnancy | The animal and human data suggest that lamivudine is a low risk to the developin More ... |
| Breast Feeding | Lamivudine is distributed into milk in humans. It is not known whether the drug More ... |
| Active Ingredient | STAVUDINE |
| Therapeutic Class | NRTI |
| Indications | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine p er tablet). Not recommended in children under 12 y ears. |
| Caution | Peripheral neuropathy , serum transaminase elevations, lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported. Concurrent administration of stavudine an More ... |
| Dose Range |
Adult greater than 60kg: 40mg every 12 hours and less than 60kg: 30mg every 12 hours. Pediatric: birth to 13 days: 0.5 mg/kg every 12 hours. 14 days and older: 1 mg/kg every 12 hours and weighing less than 30 kg. May be taken without regard to meals. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ZIDOVUDINE |
| Therapeutic Class | NRTI |
| Indications | In combination with other antiretroviral agents for the treatment of HIV infection. Zidovudine is also indicated for the prevention of maternal to fetal HIV transmission during gestation, la More ... |
| Caution | Bone marrow suppression (anemia and/or neutropenia), nausea, vomiting, anorexia, headache, malaise, asthenia and insomnia occur. Concurrent use of zidovudine and alpha-interferon, dapsone, vincrist More ... |
| Dose Range | Adult: 600mg daily in divided doses in combination with other antiretroviral agents. Pediatric: 6 weeks to 12 years: 160mg/square meter orally every 8 hours (maximum dose, 200 mg every 8 hours) in combination with other antiretroviral agents. To prevent |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |